229 related articles for article (PubMed ID: 33945142)
41. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
[TBL] [Abstract][Full Text] [Related]
42. Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells.
Flahou C; Morishima T; Higashi N; Hayashi Y; Xu H; Wang B; Zhang C; Ninomiya A; Qiu WY; Yuzuriha A; Suzuki D; Nakamura S; Manz M; Kaneko S; Hotta A; Takizawa H; Eto K; Sugimoto N
Biochem Biophys Res Commun; 2023 Jun; 662():76-83. PubMed ID: 37099813
[TBL] [Abstract][Full Text] [Related]
43. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
[TBL] [Abstract][Full Text] [Related]
44. Generation of Monoclonal iPSC Lines with Stable Cas9 Expression and High Cas9 Activity.
Liao JQ; Zhou G; Zhou Y
Methods Mol Biol; 2022; 2454():575-588. PubMed ID: 32567018
[TBL] [Abstract][Full Text] [Related]
45. Cardiac Regeneration Using Pluripotent Stem Cells and Controlling Immune Responses.
Ichimura H; Chino S; Shiba Y
Heart Lung Circ; 2023 Jul; 32(7):836-843. PubMed ID: 37029069
[TBL] [Abstract][Full Text] [Related]
46. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
Zhang Y; Sastre D; Wang F
Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
[TBL] [Abstract][Full Text] [Related]
47. Generation of an Induced Pluripotent Stem Cell Line with the Constitutive EGFP Reporter.
Butterfield KT; McGrath PS; Han CM; Kogut I; Bilousova G
Methods Mol Biol; 2020; 2155():11-21. PubMed ID: 32474864
[TBL] [Abstract][Full Text] [Related]
48. CRISPR/Cas9 system and its applications in human hematopoietic cells.
Hu X
Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
[TBL] [Abstract][Full Text] [Related]
49. Generation of a homozygous ZBTB7A knockout human induced pluripotent stem line by CRISPR/Cas9 editing.
Chen D; Song B; Cheng Y; Zhu L; Lu D; Liu N; Yang Y; Sun X
Stem Cell Res; 2021 Aug; 55():102494. PubMed ID: 34403853
[TBL] [Abstract][Full Text] [Related]
50. Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression.
Li XL; Li GH; Fu J; Fu YW; Zhang L; Chen W; Arakaki C; Zhang JP; Wen W; Zhao M; Chen WV; Botimer GD; Baylink D; Aranda L; Choi H; Bechar R; Talbot P; Sun CK; Cheng T; Zhang XB
Nucleic Acids Res; 2018 Nov; 46(19):10195-10215. PubMed ID: 30239926
[TBL] [Abstract][Full Text] [Related]
51. CRISPR/Cas9-Based Safe-Harbor Gene Editing in Rhesus iPSCs.
Yada RC; Ostrominski JW; Tunc I; Hong SG; Zou J; Dunbar CE
Curr Protoc Stem Cell Biol; 2017 Nov; 43():5A.11.1-5A.11.14. PubMed ID: 29140568
[TBL] [Abstract][Full Text] [Related]
52. CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy.
Meshitsuka S; Ninomiya R; Nagamura-Inoue T; Okada T; Futami M; Tojo A
Regen Ther; 2022 Dec; 21():442-452. PubMed ID: 36313397
[TBL] [Abstract][Full Text] [Related]
53. Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II.
Petrus-Reurer S; Winblad N; Kumar P; Gorchs L; Chrobok M; Wagner AK; Bartuma H; Lardner E; Aronsson M; Plaza Reyes Á; André H; Alici E; Kaipe H; Kvanta A; Lanner F
Stem Cell Reports; 2020 Apr; 14(4):648-662. PubMed ID: 32197113
[TBL] [Abstract][Full Text] [Related]
54. Genome Engineering for Stem Cell Transplantation.
Argani H
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
[TBL] [Abstract][Full Text] [Related]
55. HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells.
Kwon YW; Ahn HS; Lee JW; Yang HM; Cho HJ; Kim SJ; Lee SH; Yang HM; Jang HD; Kim SJ; Kim HS
Stem Cells Int; 2021; 2021():8873383. PubMed ID: 34093711
[TBL] [Abstract][Full Text] [Related]
56. FACS-assisted CRISPR-Cas9 genome editing of human induced pluripotent stem cells.
Caillaud A; Lévêque A; Thédrez A; Girardeau A; Canac R; Bray L; Baudic M; Barc J; Gaborit N; Lamirault G; Gardie B; Idriss S; Rimbert A; Le May C; Cariou B; Si-Tayeb K
STAR Protoc; 2022 Dec; 3(4):101680. PubMed ID: 36115027
[TBL] [Abstract][Full Text] [Related]
57. CGMP Compliant Microfluidic Transfection of Induced Pluripotent Stem Cells for CRISPR-Mediated Genome Editing.
Bohrer LR; Stone NE; Wright AT; Han S; Sicher I; Sulchek TA; Mullins RF; Tucker BA
Stem Cells; 2023 Nov; 41(11):1037-1046. PubMed ID: 37632456
[TBL] [Abstract][Full Text] [Related]
58. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.
Gornalusse GG; Hirata RK; Funk SE; Riolobos L; Lopes VS; Manske G; Prunkard D; Colunga AG; Hanafi LA; Clegg DO; Turtle C; Russell DW
Nat Biotechnol; 2017 Aug; 35(8):765-772. PubMed ID: 28504668
[TBL] [Abstract][Full Text] [Related]
59. Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Caron J; Pène V; Tolosa L; Villaret M; Luce E; Fourrier A; Heslan JM; Saheb S; Bruckert E; Gómez-Lechón MJ; Nguyen TH; Rosenberg AR; Weber A; Dubart-Kupperschmitt A
Stem Cell Res Ther; 2019 Jul; 10(1):221. PubMed ID: 31358055
[TBL] [Abstract][Full Text] [Related]
60. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.
Ben Jehuda R; Shemer Y; Binah O
Stem Cell Rev Rep; 2018 Jun; 14(3):323-336. PubMed ID: 29623532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
